In the pharmaceutical and biotechnology industry, there are few remaining illusions that quality is “about documentation.” For those who sign off on batch release, own contamination control strategies, or defend decisions during inspections, quality is a zone of personal accountability. A system failure may damage a company’s reputation, but a decision failure can cost an individual their career.

Over the past few years, pressure on QA and QP functions has intensified noticeably. Annex 1 has moved from guidance into daily operational reality. The rise of ATMPs, personalised medicine, and drug–device combination products is challenging traditional QMS models. At the same time, digitalisation, AI, and automation promise speed and predictability while introducing new questions: who is accountable for decisions supported by algorithms, and how are those decisions explained to an inspector?

Why has it become more complex than before

Regulatory expectations themselves have not suddenly become harsher. The environment has changed.

Development timelines are accelerating, supply chains are fragmenting, manufacturing is becoming more distributed, and quality oversight increasingly happens remotely. In this context, QA is no longer primarily a control function; it is a management and decision-making role.

Many teams face the same contradiction:
- on one hand, expectations for proactive and predictive quality;
- on the other hand, legacy processes, fragmented data, and a culture of reacting after the fact.

Adding new tools – eQMS platforms, smart sensors, AI-powered review – does not automatically resolve this tension. Without clear decision logic, defined accountability, and the ability to defend those decisions during inspection, digitalisation can amplify rather than reduce risk.

From compliance to defensible decisions

Across the industry, a subtle but important shift is taking place. The central question is no longer whether a system is compliant, but whether a specific decision can be justified under scrutiny.

This shift is particularly visible in areas now at the forefront of quality discussions:

Parametric and predictive release, where trust moves from end-product testing to process understanding.

AI in QA, where explainability, audit trails, and control of model drift become critical.

Contamination Control Strategy, treated as a living system rather than a document prepared “for Annex 1.”

Inspection readiness, reframed as scenario-based thinking instead of checklist preparation.

Experience shows that mature organisations talk less about “the right tool” and more about how decisions are made, who approves them, and what assumptions sit behind them.

Where quality leaders are looking for answers

Internal expertise is often not enough. Consultants provide frameworks, regulators define boundaries, but one question remains unresolved: how do these approaches work in practice for organisations that have already faced inspection under similar conditions?

This is why peer-to-peer formats are gaining importance – not as networking exercises, but as a way to benchmark one’s own thinking against the experience of others carrying the same level of responsibility.

In this context, the Pharma & Biotech Quality Summit, taking place in Munich in May 2026, is positioned not as a showcase of trends but as a working environment for discussing complex decisions. The agenda includes case studies on global eQMS implementation in biotech, practical discussions on quality challenges in cell and gene therapy, debates on the evolving QP role in the age of AI and accelerated development, and interactive inspection simulations where technology meets human judgement.

Notably, many sessions are led not by consultants, but by active quality leaders from multinational organisations and representatives of the regulatory community. Their focus is not on how quality should work in theory, but on how decisions were defended when questions became uncomfortable.

What this means for the industry

Gradually, a new model of professional dialogue around quality is emerging. It is less abstract, less optimistic, but far more useful. In this model, quality is understood as a system of managed trade-offs between speed, risk, and accountability.

For QA leaders, this implies a shift in role:
- from guardians of procedures to architects of decisions;
- from reactive control to predictive oversight;
- from isolated sign-off to collectively tested logic.

In the coming years, the ability to explain and defend decisions, rather than simply demonstrate compliance, is likely to become one of the most critical skills in pharmaceutical quality.

Those who are already benchmarking their approaches against peers are likely to feel far more confident navigating what comes next.